Gene Therapy Cos. Settle Patent Suit

Law360, New York (March 10, 2008, 12:00 AM EDT) -- Genomic research company Open Biosystems Inc. has settled infringement claims asserted by rivals Sigma-Aldrich Corp. and Oxford BioMedica over patents for technology heralded as key to finding a cure for neurodegenerative ailments such as Alzheimer's and Parkinson's diseases.

The LentiVector technology at issue is used to safely deliver beneficial genes to target cells for research and therapeutic purposes.

Under the deal announced on Friday, Oxford BioMedica will license patents underlying its LentiVector technology to Open Biosystems for research. Other terms of the agreement were deemed confidential...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.